# Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects

> **NCT03570346** · PHASE1 · UNKNOWN · sponsor: **Tianjin Hemay Bio-Tech Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Hemay005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03570346
- **Lead sponsor:** Tianjin Hemay Bio-Tech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-10
- **Primary completion:** 2018-10-20
- **Final completion:** 2018-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03570346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03570346, "Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03570346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*